Stryker Corporation (SYK)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $117.88B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stryker Corporation (SYK) Financials: Revenue, Profit and Cash Flow
Stryker reported revenue of $25.12B for the fiscal year ended Dec 31, 2025, up 11.2% from the year before. That year, net income was $3.25B with a net margin of 12.9%, operating cash flow was $5.04B and free cash flow was $4.28B. The quarter ended Sep 30, 2026 had revenue of $6.52B and net income of $753.00M.
Revenue and Margins
The operating margin was 19.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $11.32B, a compound annual rate of 9.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $25.12B | +11.2% | 64.0% | 19.5% | 12.9% |
| Dec 2024 | $22.59B | +10.2% | 63.9% | 16.3% | 13.2% |
| Dec 2023 | $20.50B | +11.1% | 63.7% | 19.0% | 15.4% |
| Dec 2022 | $18.45B | +7.8% | 62.8% | 15.4% | 12.8% |
| Dec 2021 | $17.11B | +19.2% | 64.1% | 15.1% | 11.7% |
| Dec 2020 | $14.35B | -3.6% | 63.1% | 15.5% | 11.1% |
| Dec 2019 | $14.88B | +9.4% | 65.1% | 18.2% | 14.0% |
| Dec 2018 | $13.60B | +9.3% | 65.7% | 18.7% | 26.1% |
| Dec 2017 | $12.44B | +9.9% | 65.7% | 18.5% | 8.2% |
| Dec 2016 | $11.32B | N/A | 66.3% | 19.2% | 14.5% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 8.7% from the year before. In the quarter ended Sep 2026, net income fell 12.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.12B | $22.59B | $20.50B | $18.45B | $17.11B | $14.35B | $14.88B | $13.60B | $12.44B | $11.32B |
| Cost of revenue | $9.05B | $8.15B | $7.44B | $6.87B | $6.14B | $5.29B | $5.19B | $4.66B | $4.26B | $3.82B |
| Gross profit | $16.07B | $14.44B | $13.06B | $11.58B | $10.97B | $9.06B | $9.70B | $8.94B | $8.18B | $7.50B |
| Research and development | $1.62B | $1.47B | $1.39B | $1.45B | $1.24B | $984.00M | $971.00M | $862.00M | $787.00M | $715.00M |
| Operating income | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | $2.22B | $2.71B | $2.54B | $2.30B | $2.17B |
| Net income | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | $1.60B | $2.08B | $3.55B | $1.02B | $1.65B |
| EBITDA | $6.31B | $4.95B | $5.06B | $3.68B | $3.27B | $2.77B | $3.34B | $3.08B | $2.71B | $2.47B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.52B | $6.59B | $6.02B | $7.17B | $6.06B | $6.02B | $5.87B | $6.44B | $5.49B | $5.42B | $5.24B | $5.82B |
| Gross profit | $4.25B | $4.50B | $3.81B | $4.63B | $3.85B | $3.84B | $3.74B | $4.17B | $3.52B | $3.42B | $3.33B | $3.70B |
| Operating income | $1.03B | $1.66B | $936.00M | $1.80B | $1.14B | $1.11B | $837.00M | $581.00M | $1.08B | $1.05B | $972.00M | $1.26B |
| Net income | $753.00M | $1.28B | $745.00M | $849.00M | $859.00M | $884.00M | $654.00M | $546.00M | $834.00M | $825.00M | $788.00M | $1.14B |
Balance Sheet
As of Dec 2025, total debt of $15.86B exceeded cash and equivalents by $11.85B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $47.84B | $42.97B | $39.91B | $36.88B | $34.63B | $34.33B | $30.17B | $27.23B | $22.20B | $20.43B |
| Current assets | $14.76B | $14.85B | $12.52B | $10.28B | $10.02B | $9.71B | $11.06B | $9.73B | $7.99B | $7.86B |
| Cash and equivalents | $4.01B | $3.65B | $2.97B | $1.84B | $2.94B | $2.94B | $4.34B | $3.62B | $2.54B | $3.32B |
| Total liabilities | $25.42B | $22.34B | $21.32B | $20.27B | $19.75B | $21.25B | $17.36B | $15.50B | $12.22B | $10.88B |
| Short-term debt | $1.00B | $1.41B | $2.09B | $1.19B | $7.00M | $761.00M | $859.00M | $1.37B | $632.00M | $228.00M |
| Long-term debt | $14.86B | $12.19B | $10.90B | $11.86B | $12.47B | $13.23B | $10.23B | $8.49B | $6.59B | $6.69B |
| Shareholder equity | $22.42B | $20.63B | $18.59B | $16.62B | $14.88B | $13.08B | $12.81B | $11.73B | $9.97B | $9.55B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $47.25B | $47.93B | $46.29B | $47.84B | $47.06B | $46.33B | $46.01B | $42.97B | $43.83B | $39.13B | $39.40B | $39.91B |
| Total liabilities | $23.79B | $23.94B | $23.31B | $25.42B | $25.27B | $25.14B | $25.08B | $22.34B | $23.68B | $19.37B | $20.23B | $21.32B |
| Cash and equivalents | $3.27B | $3.39B | $2.88B | $4.01B | $3.26B | $2.38B | $2.32B | $3.65B | $3.85B | $1.87B | $2.33B | $2.97B |
| Shareholder equity | $23.46B | $23.99B | $22.98B | $22.42B | $21.79B | $21.19B | $20.93B | $20.63B | $20.15B | $19.76B | $19.17B | $18.59B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 84.9% of operating cash flow. Dividends came to 29.9% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.04B | $4.24B | $3.71B | $2.62B | $3.26B | $3.28B | $2.19B | $2.61B | $1.56B | $1.92B |
| Capital expenditures | $761.00M | $755.00M | $575.00M | $588.00M | $525.00M | $487.00M | $649.00M | $572.00M | $598.00M | $490.00M |
| Free cash flow | $4.28B | $3.49B | $3.14B | $2.04B | $2.74B | $2.79B | $1.54B | $2.04B | $961.00M | $1.43B |
| Dividends paid | $1.28B | $1.22B | $1.14B | $1.05B | $950.00M | $863.00M | $778.00M | $717.00M | $735.00M | $568.00M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | $307.00M | $300.00M | $230.00M | $13.00M |
| Investing cash flow | -$4.87B | -$3.00B | -$962.00M | -$2.92B | -$859.00M | -$4.70B | -$1.46B | -$2.86B | -$1.61B | -$4.19B |
| Financing cash flow | $113.00M | -$525.00M | -$1.59B | -$749.00M | -$2.37B | -$11.00M | $3.00M | $1.33B | -$794.00M | $2.26B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.46B | $1.26B | $581.00M | $2.14B | $1.54B | $1.11B | $250.00M | $1.93B | $1.47B | $633.00M | $204.00M | $1.53B |
| Capital expenditures | $237.00M | $202.00M | $166.00M | $268.00M | $187.00M | $183.00M | $123.00M | $266.00M | $170.00M | $152.00M | $167.00M | $145.00M |
| Free cash flow | $1.22B | $1.06B | $415.00M | $1.88B | $1.35B | $928.00M | $127.00M | $1.67B | $1.30B | $481.00M | $37.00M | $1.38B |
Frequently Asked Questions About SYK
What is Stryker's annual revenue?
Stryker reported revenue of $25.12B for the fiscal year ended Dec 31, 2025.
How fast is Stryker's revenue growing?
Revenue was up 11.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.8%.
Is Stryker profitable?
Yes. Stryker reported net income of $3.25B for the fiscal year ended Dec 31, 2025, with a net margin of 12.9%.
How much free cash flow does SYK generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $5.04B minus capital expenditures of $761.00M produced free cash flow of $4.28B.
How much debt does Stryker have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $14.86B, short-term debt of $1.00B and cash and equivalents of $4.01B.
SYK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts